Toronto-based biopharmaceutical company, Avicanna Inc., announced that it is collaborating on a cannabinoid-based treatment for lung inflammation associated with COVID-19.
The company is working with Dr. Christine Allen’s Research Group (CARG) in the Leslie Dan Faculty of Pharmacy at the University of Toronto. Dr. Allen is a global leader is research and development of pharmaceutical formulations and has a long-standing working relationship with Avicanna for developing cannabinoid-based products.
Avicanna and CARG are hoping to fast-track the development of its pharmaceutical formulation of cannabinoids that aid in the treatment of lung inflammation in patients suffering severe symptoms of COVID-19.
“We are excited to expand our research collaboration with Dr. Allen’s group at the University of Toronto with support from the Mitacs research internship program,” said Dr. Justin Grant, executive vice-president of scientific affairs at Avicanna.
“This funding will allow us the necessary resources to complete pre-clinical studies of our most promising cannabinoid formulations. We feel this is a project that may provide a significant impact.”
Mitacs is a not-for-profit organization funded by the Government of Canada to support growth an innovation in Canada that solves business challenges through research from academic institutions.
Your email address will not be published. Required fields are marked *